National and Kapodistrian University of Athens
Μελέτη της έκφρασης του συστήματος RANKL/RANK/OPG στον καρκίνο του μαστού και θεραπευτικές προσεγγίσεις
Abstract
dc:descriptionIntroduction: Despite advances in targeted therapies, resistance to anti-human epidermal growth factor receptor 2 (HER2) treatments remains a significant challenge in breast cancer (BC) management. RANK/RANKL signaling pathway is implicated in HER2+ BC and promotes the development of resistance to anti-HER2 therapy, as well as immune evasion.Aim: This study aimed to evaluate the effectiveness of a triple-targeting regimen—Denosumab (D), Pertuzumab (P) and Trastuzumab (T)—for HER2-positive (HER2+) BC, and to assess the added value of immune checkpoint inhibitors (ICIs).Materials and Methods: A total of 120 paraffin-embedded breast cancer specimens (BC) were subjected to immunohistochemical analysis (IHC) to evaluate RANK (receptor activator of nuclear factor κΒ) expression and HER2 status. Staining intensity and the proportion of positive cells were quantified according to established scoring criteria. BT-474 HER2+ xenograft mouse models were used to assess the efficacy of combination therapies. Mice were treated with the D+T+P triple targeting regimen, and tumor volume and weight were monitored. HER2+ BC cells were cultured in a three -dimensional environment (3D) to investigate the effect of adding immune checkpoint inhibitors (ICIs), Nivolumab (N) and Ipilimumab (I), to the triple targeting regimen. Cell viability was measured following treatment by MTT assay. Expression levels of STAT3 and mTOR were analyzed in HER2+ and HER2- tissue samples via qRT-PCR to evaluate signaling pathway activation and potential mechanisms of resistance.Results : Immunohistochemical analysis revealed that HER2+ tumors displayed significantly elevated RANK expression compared to HER2 – tumors .Notably RANK+/HER2+ patients receiving triple targeting therapy exhibited a statistically significant improvement in disease free survival (DFS), whereas RANK-/HER2+ patients did not derive similar benefit. In BT-474 HER2+ xenografts, treatment with the D+T+P regimen resulted in robust reduction in both tumor volume and weight, confirming the enhanced anti-tumor efficacy of the combination therapy in vivo. Further evaluation revealed elevated STAT3 expression in HER2 – tissues and higher mTOR levels in HER2- compared to HER2+ samples, suggesting differential pathway activation across HER2 subtypes. Finally, 3D cell culture studies revealed that the addition of ICIs (Nivolumab and Ipilimumab) to the triple targeting led to a further decrease in HER2+BC cell viability, demonstrating a synergistic enhancement of the anti-tumor effect in vitro (D+T+P+N+I).Conclusions: These results underscore the pivotal role of the RANK–receptor activator of NF- κB ligand (RANKL) axis in tumor growth and immune regulation, supporting the use of triple-targeting therapy and suggesting enhanced benefits with the inclusion of ICIs to potentially overcome therapeutic resistance in HER2+ BC.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Simatou, Aristofania
- Σιμάτου, Αριστοφάνια
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/62016